Clement Luming Ren, MD, MBA
Professor of Pediatrics (Pulmonary Medicine) at the Children's Hospital of Philadelphia
Department: Pediatrics
Contact information
Children's Hospital of Philadelphia
Division of Pulmonary and Sleep Medicine
The Hub for Clinical Collaboration
3501 Civic Center Blvd
Philadelphia, PA 19104
Division of Pulmonary and Sleep Medicine
The Hub for Clinical Collaboration
3501 Civic Center Blvd
Philadelphia, PA 19104
Office: 215-590-3749
Email:
renc@chop.edu
renc@chop.edu
Education:
AB (Biophysics)
The University of California, Berkeley, 1983.
MD (Medicine)
The University of Chicago, Pritzker Medical School, 1987.
M.B.A. (Medical Management)
The University of Rochester, Simon School of Business, 2016.
Permanent linkAB (Biophysics)
The University of California, Berkeley, 1983.
MD (Medicine)
The University of Chicago, Pritzker Medical School, 1987.
M.B.A. (Medical Management)
The University of Rochester, Simon School of Business, 2016.
Description of Clinical Expertise
I have cared for children with a variety of respiratory disease for over 25 years, but I have focused on children with cystic fibrosis and respiratory complications of prematurity.Description of Other Expertise
In addition to advancing knowledge through research, I have helped advance care through leadership and service in the CF Foundation and American Thoracic Society, where I have served on and chaired committees focused on clinical issues such as telehealth, led the development of clinical practice guidelines, and headed quality improvement networks. I also am an Associate Editor for Pediatric Pulmonology and a member of the American Board of Pediatrics Sub-Board for Pediatric Pulmonology.Description of Research Expertise
My research utilizes infant/preschool pulmonary function tests (PFTs) to study outcomes of pediatric respiratory diseases such as cystic fibrosis (CF) and bronchopulmonary dysplasia. I have led several multicenter observational cohort studies using infant/preschool PFTs as the primary outcome measure. More recently, I have expanded my work to encompass imaging using chest MRI and the use of remote monitoring applications for patient reported outcomes. My other area of scholarly activity has been CF epidemiology, where I have used the CF Foundation Patient Registry for numerous analyses of outcomes and risk factors for more severe lung disease. I have had a particular interest in outcomes of CF newborn screening, especially those of infants with a positive newborn screen but inconclusive diagnostic testing. In summary, I have developed extensive experience and expertise in the design and conduct of multicenter observational cohort studies and interventional trials in infants and young children using advanced PFTs and imaging as an outcome measure, epidemiologic studies using patient registry data, and development of clinician resources such as clinical practice guidelines.Selected Publications
Carroll BJ, Ostrenga JS, Fink AK, Antos NJ, Cromwell EA, Ren CL: Clinical outcomes at 9-10 years of age in children born with cystic fibrosis transmembrane conductance regulator related metabolic syndrome. Pediatr Pulmonol Available online ahead of print 2024.Martiniano SL, Wu R, Farrell PM, Ren CL, Sontag MK, Elbert A, McColley SA.: Late Diagnosis in the Era of Universal Newborn Screening Negatively Affects Short- and Long-Term Growth and Health Outcomes in Infants with Cystic Fibrosis. J Pediatr 262: 113595, Jul 2023.
Cogen JD, Sanders DB, Slaven JE, Faino AV, Somayaji R, Gibson RL, Hoffman LR, Ren CL.: Antibiotic Regimen Changes During Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment. Ann Am Thorac Soc Page: Available online, Jun 2023.
Tsukahara K, Scully T, McDonough J, Boas H, DeMauro SB, Ren CL, Allen J.: Reactance inversion in a cohort of former preterms: Physiology or artifact? Pediatr Pulmonol 58: 2681-2684, Jun 2023.
VanDevanter, D. R., Zemanick, E. T., Konstan, M. W., Ren, C. L., Odem-Davis, K., Emerman, I., Young, J., Mayer-Hamblett, N., Chec-Sc Study Group: Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials. J Cyst Fibros 22(4): 652-655, 2023.
McGarry ME, Ren CL, Wu R, Farrell PM, McColley SA.: Detection of disease-causing CFTR variants in state newborn screening programs. Pediatr Pulmonol 58: 465-74, 2023.
Rehani MR, Marcus MS, Harris AB, Farrell PM, Ren CL.: Variation in cystic fibrosis newborn screening algorithms in the United States. Pediatr Pulmonol 58: 927-33, 2023.
R List, GM Solomon, S Bichl, BJ Horton, S Shen, B Corcoran, H Sadeghi, MT Britto, C Ren, D Albon, and CFLN Collaboration Group FIES/SIES Innovation Lab: Improved recognition of lung function decline as signal of cystic fibrosis pulmonary exacerbation: a Cystic Fibrosis Learning Network Innovation Laboratory quality improvement initiative. BMJ Open Qual 28: e002466, 2023.
Cogen, J. D., Sanders, D. B., Slaven, J. E., Faino, A. V., Somayaji, R., Gibson, R. L., Hoffman, L. R., Ren, C. L.: Antibiotic Regimen Changes during Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment. Ann Am Thorac Soc 20(9): 1293-1298, 2023.
Corcoran, A., Faig, W., Ren, C. L.: Clinical features associated with pulmonary exacerbation diagnosis in infants and young children with cystic fibrosis. Pediatr Pulmonol 2023.